New insight of EGFR-TKI therapy in NSCLC: a novel treatment strategy and the mechanistic study of acquired resistance

New insight of EGFR-TKI therapy in NSCLC: a novel treatment strategy and the mechanistic study of acquired resistance

Cheong, Hio Teng. === Thesis M.Phil. Chinese University of Hong Kong 2015. === Includes bibliographical references (leaves 127-139). === Abstracts also in Chinese. === Title from PDF title page (viewed on 16, November, 2016).

Bibliographic Details
Other Authors:	Cheong, Hio Teng (author.)
Format:	Others
Language:	English Chinese
Published:	2015
Subjects:
Online Access:	http://repository.lib.cuhk.edu.hk/en/item/cuhk-1291849

Similar Items

EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
by: Xuan Zhu, et al.
Published: (2019-10-01)

The Mechanism of Resistance to EGFR-TKI in NSCLC and Exploration to Overcome the Resistance
by: Baohui HAN, et al.
Published: (2009-12-01)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
by: Wenxian Wang, et al.
Published: (2019-02-01)

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
by: Lihao Zhao, et al.
Published: (2019-12-01)

Gene Fusions as Acquired Resistance Mechanisms of EGFR-TKI
by: Yi SHAO, et al.
Published: (2020-05-01)

Treatment of Advanced NSCLC with Unknown EGFR Gene Status __ TKI or Chemotherapy?
by: Xiaoqing LIU, et al.
Published: (2014-10-01)

Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC.
by: Michael E Goldberg, et al.
Published: (2018-01-01)

Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy
by: Nobuhiko Seki, et al.
Published: (2019-01-01)

IL-22 Confers EGFR-TKI Resistance in NSCLC via the AKT and ERK Signaling Pathways
by: Xiaomeng Wang, et al.
Published: (2019-11-01)

Treatment Choice After EGFR-TKI Resistance
by: Junling LI
Published: (2013-10-01)

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
by: Silvia La Monica, et al.
Published: (2017-12-01)

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
by: Shang-Gin Wu, et al.
Published: (2020-09-01)

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
by: Da Hyun Kang, et al.
Published: (2020-06-01)

New data highlighting the efficacy and safety outcomes of third‐generation EGFR‐TKI in NSCLC patients with rare EGFR mutations
by: Weisan Zhang, et al.
Published: (2020-03-01)

How to Make the Choice in the Retreatment of EGFR-TKI for Advanced NSCLC Patients Who Benefited from Prior Gefitinib Therapy: the Original Drug or Switching to A Second EGFR-TKI?
by: Chuanhao TANG, et al.
Published: (2013-07-01)

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
by: Shang-Gin Wu, et al.
Published: (2018-02-01)

Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials
by: Li Sun, et al.
Published: (2021-01-01)

Triple Trouble: A Case of Multiple Resistance Mechanisms after First Generation EGFR-TKI in NSCLC
by: Mike Ralki, et al.
Published: (2019-08-01)

Up-Regulated FGFR1 Expression as a Mediator of Intrinsic TKI Resistance in EGFR-Mutated NSCLC
by: Kristine Raaby Gammelgaard, et al.
Published: (2019-03-01)

The Study of NSCLC Cell Response and the Drug-Drug Interaction upon EGFR-TKI Small Molecular Treatment
by: Wang, Hsian-Yu, et al.
Published: (2017)

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
by: Wen-Shuo Wu, et al.
Published: (2014-06-01)

Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib
by: Yaming Liu, et al.
Published: (2021-05-01)

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
by: Rajeswara Rao Arasada, et al.
Published: (2018-08-01)

Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy  in Advanced NSCLC Patients with EGFR Mutations
by: Minjiang CHEN, et al.
Published: (2019-02-01)

Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated NSCLC patients who develop brain metastasis
by: Wenxian Wang, et al.
Published: (2018-10-01)

First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Qiang Wu, et al.
Published: (2021-04-01)

Exploitation and Mechanistic Validation of Drug-combination Strategies to Overcome EGFR-inhibitor resistance in NSCLC cells
by: Wang, Yu-Chieh
Published: (2008)

Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC
by: Hou H, et al.
Published: (2019-06-01)

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
by: Dario Presutti, et al.
Published: (2015-01-01)

Molecular mechanism of acquired drug resistance in the EGFR‐TKI resistant cell line HCC827‐TR
by: Tao Yu, et al.
Published: (2020-05-01)

Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells
by: Donglei Liu, et al.
Published: (2014-03-01)

Anti-cancer synergy of targeting pyruvate dehydrogenase kinase 1 (PDK1) in combination with EGFR-TKi in NSCLC therapy
by: Yang, Zheng
Published: (2018)

Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
by: Mikkel G. Terp, et al.
Published: (2021-07-01)

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
by: Qiming Wang, et al.
Published: (2019-06-01)

Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.
by: Zhijie Wang, et al.
Published: (2014-01-01)

Advances in the Research of Autophagy in EGFR-TKI Treatment and Resistance  in Lung Cancer
by: Qicheng ZHANG, et al.
Published: (2016-09-01)

The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
by: Cheng WC, et al.
Published: (2021-01-01)

Concurrent use of anlotinib overcomes acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant non‐small cell lung cancer
by: Chen Zhang, et al.
Published: (2021-10-01)

Liquid biopsy uncovers distinct patterns of DNA methylation and copy number changes in NSCLC patients with different EGFR-TKI resistant mutations
by: Hoai-Nghia Nguyen, et al.
Published: (2021-08-01)

Conventional real-time PCR-based detection of T790M using tumor tissue or blood in patients with EGFR TKI-resistant NSCLC
by: Wu Y, et al.
Published: (2017-07-01)

Cannot write session to /tmp/vufind_sessions/sess_qkhg610or6nu1hak6rko7tiv1l